Skip to content

Monitor-Guided Analgesia During General Anesthesia - Part II

Investigation of the Effect of Opioid Titration Guided by Analgesia Indices During Total Intravenous Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03380949
Acronym
MOGADA-II
Enrollment
96
Registered
2017-12-21
Start date
2017-12-08
Completion date
2018-06-07
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Nociceptive Pain, Opioid Use, Pain, Pain, Postoperative

Keywords

Analgesia, Monitoring, Opioid, Sufentanil, Sevoflurane

Brief summary

This prospective randomized clinical trial evaluates the effects of a monitor-guided opioid analgesia during general anesthesia. To date no standard-monitoring device exists to specifically reflect the analgesic component of general anesthesia. Quality and safety of general anesthesia are of major clinical importance and should be improved by limiting the opioid analgesic's dosage to the minimum amount needed. The study compares the effects of monitoring nociception during general anesthesia with different innovative techniques in comparison to routine clinical practice.

Detailed description

This prospective randomized clinical study aims to investigate the effects of a monitor-guided opioid analgesia during general anesthesia by different monitoring systems in comparison to routine clinical practice. Many surgical procedures require general anesthesia. The main components of general anesthesia are hypnosis and analgesia, and anesthesiologists usually combine a hypnotic drug with an opioid analgesic. Until today, however, there is no standard-monitoring of nociception to specifically reflect the analgesic component of general anesthesia. In clinical practice the opioid dosage is chosen by clinical judgment of the attending anesthesiologist based upon changes of heart rate, blood pressure, pupil size, lacrimation and sweating of the patient. On the one hand, underdosage of opioids can cause nociception leading to an increased sympathetic tone, increase of plasma levels of stress hormones, nociceptive movements as well as increase postoperative pain. On the other hand, overdosage of opioids can lead to drug side effects such as nausea and vomiting, hemodynamic instability, an increase in recovery times, immunosuppression and an increase in postoperative pain by opioid-induced-hyperalgesia. Quality and safety of general anesthesia are of major clinical importance and can be improved by limiting the administration of opioid analgesics to the optimal individual dose needed. In the last years, different analgesia monitoring devices have been developed for monitoring nociception. The present study evaluates the effects of the administration of opioids during general anesthesia guided by three different monitoring systems in comparison to routine clinical practice. All patients will receive general anesthesia with propofol guided by bispectral index (BIS) with a target of BIS values between 40 and 60. Opioid administration will be guided by one of three analgesic monitoring devices or the interpretation of clinical signs by the attending anesthesiologist in the control group. After institutional approval by the Ethics committee of the Medical Board of the City of Hamburg, Germany and obtaining patients' written informed consent we randomize elective patients with major abdominal surgery for open radical prostatectomy into one of four treatment groups.

Interventions

PROCEDUREOpioid administration (remifentanil) in intervention group

Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.

PROCEDUREOpioid administration (remifentanil) in control group

Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants are not informed about the group assignement (intervention takes place in general anesthesia). Outcome assessors are persons without knowledge on former treatment in intervention/control group.

Intervention model description

Participants are assigned to intervention groups by chance

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Radical open abdominal prostatectomy scheduled in the operation theater where the study is conducted * \> 18 years

Exclusion criteria

* Chronic opioid therapy * Beta blocker and digitalis therapy * Eye disease with affection of pupil reactivity * Pacemaker therapy * Higher degrees of cardiac arrhythmias, e.g. atrial fibrillation * Pre-operative medication with steroids

Design outcomes

Primary

MeasureTime frameDescription
Intraoperative opioid consumption1 dayCompares the amount of intraoperative opioid administration (remifentanil) per minute of general anesthesia and per kg bodyweight between groups.

Secondary

MeasureTime frameDescription
Time to Fit-for-discharge1 dayPostoperative recovery time: Time interval between postoperative tracheal extubation and the patient reaching fit-for-discharge criteria. criteria from the PACU to the ward.
Postoperative pain level1 dayPostoperative pain level measured with the highest score in numeric pain rating scale (NRS).
Time to extubation1 dayPostoperative recovery time: Time interval between end of operation and tracheal extubation of the patient.
Patient satisfaction2-21 daysPatient satisfaction with the general anesthesia and pain management evaluated by a numeric rating scale.
Release of stress hormones1 dayAmount of perioperative plasma level of cortisol and ACTH.
Postoperative opioid administration1 dayAmount of postoperative opioid administration (piritramid) in the postanesthesia care unit (PACU). Piritramid is given if NRS score is \> 3.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026